NEW YORK, July 20, 2016 /PRNewswire/ --
The Scientific and Technical Instruments industry is a very competitive landscape given the demand for related apparatus. Companies in this space are always competing to produce high-quality products while controlling manufacturing costs. In today's pre-market research, Stock-Callers.com shifts focus onto Trimble Navigation Ltd (NASDAQ: TRMB), Garmin Ltd (NASDAQ: GRMN), Keysight Technologies Inc. (NYSE: KEYS), and Cepheid (NASDAQ: CPHD). Learn more about these stocks by accessing their free notes at:
On Tuesday, Sunnyvale, California headquartered Trimble Navigation Ltd's stock dropped 0.47% to close the day at $25.43 with a total volume of 960,591 shares traded. The Company's shares have advanced 0.63% in the previous three months and 18.55% on an YTD basis. The stock is trading 1.84% above its 50-day moving average and 11.78% above its 200-day moving average. Additionally, shares of Trimble Navigation, which provides technology solutions to enhance the work processes of professionals and field mobile workers worldwide, have a Relative Strength Index (RSI) of 56.86.
On June 28th, 2016, research firm JP Morgan downgraded the Company's stock rating from 'Overweight' to 'Neutral'.
On July 18th, 2016, Trimble Navigation and CSCEC No. 1 Building Group Corporation Limited, one of the largest building contractors in China, announced plans to collaborate to explore the applications of mixed-reality technology in the Architecture, Engineering and Construction industry. As part of Trimble's Mixed-Reality Pilot Program, CSCEC Group 1 is the first organization in China to use Microsoft HoloLens and Trimble Mixed-Reality solutions. TRMB complete notes are just a click away at:
Shares in Schaffhausen, Switzerland-based Garmin Ltd rose 0.51%, finishing the session at $45.66. The stock recorded a trading volume of 702,922 shares. The Company's shares have gained 8.51% in the last month, 8.49% in the previous three months, and 25.96% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 9.39% and 20.53%, respectively. Furthermore, shares of Garmin, which together with its subsidiaries, designs, develops, manufactures, markets, and distributes a range of navigation, communication, and information devices worldwide, have an RSI of 71.47.
On July 07th, 2016, Garmin International Inc., a unit of Garmin Ltd., announced the gWind™ Wireless 2 Transducer, a new easy-to-install wind solution for masts up to 50 feet that wirelessly sends essential wind data to GNX™ Wind instruments or a compatible Garmin GPSMAP® chartplotter, eliminating the need to run wires through the mast. The gWind Wireless 2 is the first and only wireless wind transducer on the market that connects directly to a compatible chartplotter. The complimentary notes on GRMN can be accessed at:
Santa Rosa, California headquartered Keysight Technologies Inc.'s stock finished 0.20% lower at $29.26 at the close, with a total volume of 546,892 shares traded. The Company's shares have advanced 7.34% in the previous three months and 3.28% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 0.51% and 4.05%, respectively. Additionally, shares of Keysight Technologies, which provides electronic design and test solutions to communications and electronics industries in the United States and internationally, have an RSI of 55.51.
On July 11th, 2016, Keysight Technologies introduced its Signal Optimizer software -the industry's first and only all-in-one software for calibration, signal creation and signal analysis of 5G candidate waveforms. Register for free on Stock-Callers.com and activate the trade alert on KEYS at:
Shares in Sunnyvale, California headquartered molecular diagnostics company, Cepheid, ended Tuesday's session 0.70% lower at $32.44 with a total volume of 561,247 shares traded. The stock has advanced 11.75% in the last month. The Company's shares are trading 11.47% above their 50-day moving average and 0.05% above their 200-day moving average. Moreover, shares of Cepheid, which develops, manufactures, and markets integrated systems for testing in the clinical and non-clinical markets, have an RSI of 58.72.
On June 30th, 2016, Cepheid announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for expanded claims for Xpert® Carba-R, the first FDA-cleared test for detection of carbapenem resistance genes of multidrug resistant 'superbugs'. Following initial clearance in March for detection and differentiation of carbapenemase genes in pure bacterial isolates, the latest clearance extends use of the assay to the analysis of direct rectal swab specimens, and positions Xpert Carba-R as a valuable tool for the identification of colonized patients and as an aid to infection control efforts. Get free access to your notes on CPHD at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA